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Purpose/Objective: To evaluate the first clinical and dosimetry data 
of a new afterloading machine using a Co-60 source. 
Materials and Methods: Patients with prostate cancer were treated 
by combined external beam radiotherapy (EBRT) followed by a 
brachytherapy boost: After 46Gy EBRT to the prostate two fractions of 
9 Gy were applied, each 2 weeks apart. In 2008 a new afterloading 
machine (Multisource®, Eckert & Ziegler BEBIG, Germany) was 
installed using a Co-60 source. Toxicity data were compared to a 
cohort of 131 patients treated with Ir-192 and the same fractionation 
scheme at our institution from 2001 – 2008. 
Results: A total of 117 patientswere treated with Co-60 from 01/2008-
10/2012. Median age at diagnosis was 72 years. Patients had a mean 
PSA value of 25.5 ng/ml and a mean Gleason-score of 7.2 (< 6: 16%, 7: 
65%, > 8: 19%). High risk tumours were present in 53%, intermediate 
risk in 42% and low risk in 5% of the patients. Neo-/adjuvant 
antihormonal therapy was given in 38.2%. Mean prostate volume was 
31.7ml and mean IPSS was 7.4 at presentation. DVH parameters (mean 
values) for brachytherapy were D90: 8.97 Gy, COIN: 0.68. Dmax for 
rectal wall was 8.0 Gy and 11.8 Gy for the urethra. The TRAK value 
was 0.27 cGy x m2. Toxicities were evaluated according to CTCAE 
v3.0. Most frequent acute GU toxicities were an increase in urinary 
frequency (49%, 19.6% and 5.9%, grade I / II / III), painful voiding 
(45%, 4% and 4%, grade I / II / III) and urinary bleeding after 
interstitial brachytherapy (36.5% and 11.5%, grade I / II). Acute GI 
toxicity presented with proctitis (12% and 6%, grade I / II) and 
diarrhea (14% grade I). No acute grade IV toxicity was reported. Late 
toxicities are not presented because of the short follow-up (median 
13.7 months). In comparison with the patients formerly treated with 
Ir-192 no significant increase in acute adverse events were reported 
(39.2% vs. 29.8% for grade II and 9.8% vs. 5.3% for grade III, Co-60 vs. 
Ir-192). The comparison of the dosimetry data is still under evaluation 
and will be presented at the meeting. 
Conclusions: Using Co-60 for a HDR-brachytherapy boost after EBRT is 
a feasible technique in prostate cancer patients with no excess of 
toxicities in regard to Ir-192. Due to the short follow-up long term 
data on clinical outcome have to be awaited.  
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Purpose/Objective: The standard for the determination of post-
implant dose parameters of trans rectal ultrasound-guided permanent 
radioactive I-125 implantation of the prostate (BT) is a CT-based 
identification of the implanted seeds and of the prostate and organs 
at risk. However, while CT depicts the seeds very clearly, the contour 
of the prostate cannot reliably be identified, due to poor soft tissue 
contrast.In this study, we evaluated added use of T2-weighted MR 
images (MRI) for prostate delineation, while the CT were used for 
seed identification.  
Materials and Methods: Thirteen patients underwent both CT and MRI 
30 days after BT. CT and MRI were manually registered based on seed 
localization using the registration tool in Eclipse V8.9. Registration 
was performed independently by 2 physicists. One physician contoured 
the prostate on CT and MRI on different days without seeing the other 
image modality. The evaluation was based on the minimum dose to 90 
percent of the prostate (D90) and the percentage of the prostate 
receiving 100 percent of the prescribed dose (V100).The D90 and V100 
were computed for CT-based (CT was used for seed localization and 
prostate delineation) and for CT/MRI based postplanning (CT was used 
for seed localization and MRI for prostate delineation). The variability 
of the dosimetric parameters based on registration uncertainty was 
estimated based on the variation of the D90 and V100 between the 2 
physicists performing the registration. 
Results: In contrast to other reports, we found a sufficient seed 
visibility on MRI for an effective registration based on seed 
localization. The major difficulty during registration was that the 
prostate shape varied in some cases and consequently not all seeds 
could be matched. This created an uncertainty for the registration, 
and depending on which seed group was chosen to match, the 2 
physicists arrived at different registrations. Eliminating the 2 patients 
for which the registration was not possible, we found that the mean 
difference in the D90 and V100 between the CT-based and the 
CT/MRI-based post-planning was 4% and 9% (max deviation -18% and 
30%) respectively. The mean difference in the D90 and V100 between 
the CT/MRI based post-planning by the 2 physicists (registration 
uncertainty) was 3% and 2% (max value 10% and 5%) respectively. 
Conclusions: MRI is valuable in contouring more precisely the prostate 
and therefore getting a more realistic dosimetric characterization of 
the implantation. However, the registration adds an uncertainty to 
the postplanning process and this uncertainty must be understood to 
obtain meaningful data. We found that it is important to be critical 
during the registration and to perform a CT/MRI based postplanning 
only for those patients for which we feel an optimal registration can 
be performed. Our preliminary findings show that if this is done, there 
is a gain in post-planning dosimetric accuracy. Future investigations 
will evaluate the use of 3D MRI images to see if the uncertainty on the 
CT/MRI registration can be further reduced. 
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Purpose/Objective: The nonmelanoma skin cancers are among the 
most common tumours, especially in older patients. The classic 
approach is surgery, but the development experienced by high dose 
rate brachytherapy, achieves similar cure rates and cosmetic results. 
With this approach, at the Hospital La Fe, the Valencia Applicators are 
used as accessories of the Nucletron HDR microSelectron Unit, which 
allow treatment of lesions up to 4 mm deep and 3 cm in maximum 
diameter. The purpose of this work was to assess the oncologic and 
cosmetic results, and acute toxicity (RTOG/CTCv3), in patients with 
nonmelanoma skin carcinoma treated with Valencia Applicator with a 
new regime of hypofractionation. 
Materials and Methods: We retrospectively reviewed the results of 48 
basal cell carcinomas in 33 patients treated at our institution between 
January 2008 and March 2010, with a follow-up between 24 and 54 
months (30% of the patients with a follow-up longer than 3 years). 
Most of the patients (55%) were male, and 70% were over 70 years. 
The treatment protocol includes the determination of the area (GTV-
CTV) by a dermatologist with the dermatoscope and depth ultrasound. 
The treatment schedule consists of 7 Gy delivered in 6 by 7 Gy or 7 by 
6 Gy fractions, scheduled in 2 sessions per week, reaching 42 Gy . The 
treatment is prescribed at 3 mm depth in those lesions whose depth is 
3 mm or less, and at 4 mm to lesions between 3 mm and 4 mm. 
Results: Of the 48 tumours treated, 35 were located in the facial and 
13 elsewhere. Practically all the lesions (47/48) resulted in a depth 
less than 3 mm. Local control at 3 months has been excellent (47/48) 
and registered a high dermal toxicity was grade 1 (RTOG/CTCAEv3), 
having being resolved with topical treatment at 4 weeks in all but one 
case that required 2 months. The esthetical result (RTOG/CTCAEv3) 
was magnificent in all cases. 
Conclusions: In our experience, the HDR-BT with Valencia Applicator 
in hypofractionated regime provides excellent results, for both 
cosmetic and local control in the short term, with little toxicity. 
Moreover the hypofractionation facilitates compliance with treatment 
comfort in elderly patients. 
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